Monday, March 15, 2021 2:22:25 PM
https://www.proactiveinvestors.com//companies/news/901356/avalon-globocare-seeking-to-tap-the-power-of-cells-to-fight-cancer-and-coronavirus-901356.html?SNAPI
While it has been quiet so far in 2021, Avalon Globocare had a busy time in the final quarter of 2020
In October, the company announced the formation of a strategic collaboration for the global distribution of coronavirus (COVID-19) point-of-care antibody rapid test devices. It noted that the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology (antibody) POC test for COVID-19 using fingerstick blood samples approved by the US Food and Drug Administration (FDA).
The FDA has issued an emergency use authorization (EUA) for the test device as well as for the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device. Under the agreement, Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for both tests. As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional.
In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s president and CEO, Dr David Jin, highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021.
In September, Avalon had announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform as a potential therapy for COVID-19 which is caused by the SARS-CoV-2 virus. The company said it believes that its MSC platform could offer a unique and efficacious approach to treat the potentially fatal acute respiratory distress syndrome, multi-system inflammatory syndrome and cytokine storm-related to severe cases of COVID-19.
In addition to being a potential therapy for COVID-19, the company said the platform would also be developed to treat bone marrow transplant-related complications of acute graft versus host disease (aGVHD).
In the December Nature Biopharma Dealmakers issue, Dr Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial.
At the start of October, Avalon said it had expanded the Phase 1 clinical trial of its relapsed/refractory B-cell lymphoblastic leukemia treatment, AVA-001, to include enrollment of patients with relapsed/refractory non-Hodgkin lymphoma. AVA-001 is a chimeric antigen receptor (CAR) T-cell (a type of white blood cell) therapy and allogeneic mesenchymal stromal cell (MSC, or connective tissue) therapy, which is designed to improve the body’s capacity to kill cancer cells.
In June, Avalon had successfully completed a first-in-human trial of the drug, and found that nine out of 10 patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) achieved complete remission within one month.
And at the end of December, Avalon also provided an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.
The collaboration brings together BOKU’s S-layer nanotechnology with Avalon’s expertise in biomanufacturing, cell therapy engineering, and clinical development. Avalon plans to leverage the pioneering work of Professor Uwe B. Sleytr, a world-renowned scientist and pioneer in nanobiotechnology, who is among the foremost experts on basic and applied surface layer (S-layer) technology, and Professor Emeritus in the Department of Nanobiotechnology at BOKU. Professor Sleytr is also a member of Avalon’s Scientific and Clinical Advisory Board.
Avalon and BOKU are establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation.
Recent ALBT News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 09:10:10 PM
- Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report • GlobeNewswire Inc. • 05/24/2024 09:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 12:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:17 PM
- Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 04/22/2024 01:00:00 PM
- Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:49:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:30:46 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/20/2023 08:18:23 PM
- Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 01:15:01 PM
- Apple Approves Use of Avalon GloboCare’s KetoAir Mobile Application • GlobeNewswire Inc. • 10/04/2023 01:00:00 PM
- Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device • GlobeNewswire Inc. • 09/13/2023 01:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/08/2023 09:19:22 PM
- News Brief: Avalon GloboCare Corp. • AllPennyStocks.com • 09/05/2023 03:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2023 12:56:24 PM
- Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT) • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- News Brief: Avalon GloboCare Corp. • AllPennyStocks.com • 08/30/2023 02:26:00 PM
- Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis • GlobeNewswire Inc. • 08/30/2023 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/29/2023 08:55:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 01:11:56 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM